Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,943,751 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,943,751 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,942,323 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,942,323 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,966,320 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,966,320 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,976,036 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,976,036 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,958,949 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,958,949 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 17,637 | $155.46 | $2,741,932.68 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,204,168 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.92 to $155.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 14, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,606 | $154.49 | $1,020,562.92 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,221,805 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.92 to $154.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 284 | $158.51 | $45,018.06 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228,411 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.47 to $158.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 41,020 | $157.39 | $6,456,228.04 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228,695 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.21 to $158.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 43,728 | $156.93 | $6,862,396.83 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,269,715 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.21 to $157.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,757 | $155.57 | $1,673,443.90 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,313,443 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.20 to $156.165, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,424 | $154.68 | $684,293.26 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,324,200 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.20 to $155.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,593 | $153.78 | $860,065.25 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,328,624 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.20 to $154.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 23,878 | $155.86 | $3,721,539.12 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334,217 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.75 to $156.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,513 | $155.25 | $2,563,692.79 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,358,095 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.71 to $155.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,053 | $153.69 | $1,698,702.41 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374,608 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.51 to $154.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 19,864 | $153.25 | $3,044,165.95 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,385,661 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.51 to $153.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 22:08 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,553 | $151.80 | $235,745.71 |
DisclosureSEC source: 0001576280-21-000041 · wf-form4_161843809872109.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,405,525 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.51 to $152.205, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 09, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 305 | $158.79 | $48,431.59 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,407,078 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.72 to $158.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 09, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,225 | $157.49 | $1,610,298.44 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,407,383 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.29 to $158.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 09, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 36,600 | $157.03 | $5,747,415.12 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,417,608 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.28 to $157.275, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 09, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,866 | $155.89 | $2,161,533.30 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454,208 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.27 to $156.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,330 | $161.97 | $2,645,043.59 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468,074 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.83 to $162.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 57,584 | $161.14 | $9,279,085.76 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,484,404 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.83 to $161.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 35,805 | $160.13 | $5,733,594.29 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,541,988 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.83 to $160.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,127 | $159.48 | $2,093,462.46 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577,793 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.83 to $159.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,200 | $162.16 | $194,592.00 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,590,920 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,771 | $160.35 | $444,319.60 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,592,120 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.11 to $161.105, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 8,331 | $160.01 | $1,333,024.98 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,594,891 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.11 to $160.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,055 | $158.52 | $801,320.12 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,603,222 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.11 to $159.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,474 | $157.72 | $2,598,297.40 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,608,277 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.11 to $158.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 21:51 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,012 | $156.75 | $472,129.49 |
DisclosureSEC source: 0001576280-21-000039 · wf-form4_161800508778895.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,624,751 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.11 to $157.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 500 | $162.83 | $81,417.00 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 15 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,627,763 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.81 to $162.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,100 | $161.68 | $177,850.42 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,628,263 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.37 to $162.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,229 | $160.70 | $1,483,065.23 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629,363 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.37 to $161.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,575 | $160.02 | $732,090.13 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638,592 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.37 to $160.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,200 | $158.46 | $190,156.08 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,643,167 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.22 to $159.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,213 | $157.28 | $662,612.64 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,644,367 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.14 to $157.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 15,887 | $156.75 | $2,490,214.17 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648,580 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.14 to $157.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,689 | $155.55 | $2,129,377.34 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,664,467 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.10 to $156.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,718 | $154.78 | $1,194,558.08 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,678,156 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.09 to $155.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 700 | $153.29 | $107,300.97 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,685,874 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.80 to $153.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 649 | $162.73 | $105,613.07 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,686,574 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.56 to $163.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,156 | $161.84 | $187,083.23 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,687,223 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.51 to $162.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,159 | $160.89 | $186,473.60 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,688,379 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.45 to $161.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 91,469 | $159.94 | $14,629,798.83 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,538 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.39 to $160.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 22:40 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,642 | $158.79 | $1,213,434.97 |
DisclosureSEC source: 0001576280-21-000010 · wf-form4_161170080072759.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,781,007 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.38 to $159.315, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,722 | $164.01 | $1,758,540.95 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 26 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,788,649 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F19 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $163.63 to $164.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,530 | $162.71 | $1,062,517.85 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 25 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,799,371 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F18 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $162.6206 to $163.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 118,726 | $162.08 | $19,243,691.84 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 24 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,805,901 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F17 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $161.59 to $162.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 33,422 | $161.17 | $5,386,697.27 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 23 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,924,627 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $160.59 to $161.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,806 | $160.29 | $610,076.68 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 22 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,958,049 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $159.59 to $160.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 14,083 | $167.77 | $2,362,689.42 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 21 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,961,855 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $167.40 to $168.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,149 | $166.83 | $859,024.66 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 20 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,975,938 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $166.39 to $167.385, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:46 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,104 | $165.82 | $1,841,290.82 |
DisclosureSEC source: 0001576280-21-000009 · wf-form4_161127639711015.xml · nonDerivative · entry 19 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,981,087 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $165.365 to $166.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.